Tempest Therapeutics (NASDAQ:TPST) stock is heading higher on Thursday after the clinical-stage oncology company announced plans to show off new study data.
Tempest Therapeutics will be holding a conference call at 8:30 a.m. Eastern Time today. This will cover its Phase 1b/2 combination study of amezalpat with atezolizumab and bevacizumab.
Amezalpat is a drug in development as a treatment for hepatocellular carcinoma (HCC). This is a type of cancerous tumor that develops in the liver. The conference call this morning will go over new data from the global, randomized Phase 1b/2 clinical trial.
How This Affects TPST Stock Today
With this news comes heavy trading of TPST stock as investors are excited about the company’s cancer treatment data. This has more than 10 million shares of the stock trading as of this writing. That’s well above its daily average trading volume of about 800,000 shares.
TPST stock is up 44.8% as of Thursday morning. The stock was down 35.4% year-to-date when markets closed on Tuesday, which was the previous day of trading due to the Juneteenth holiday on Wednesday.
Investors who are seeking out even more of the most recent stock market stories are going to want to stick around!
InvestorPlace is home to all of the hottest stock market coverage that traders need to know about on Thursday! Among this is what’s going on with SMX (Security Matters) (NASDAQ:SMX) stock today, the biggest pre-market stock movers this morning and more. All of this info is ready to go at the links below!
More Stock Market News for Thursday
- Why Is SMX (Security Matters) (SMX) Stock Up 70% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
- NIO Stock Fans Should Get Ready for a New Nio Phone
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
